Latest news with #TheEnsignGroup
Yahoo
16-05-2025
- Business
- Yahoo
2 Russell 2000 Stocks with Promising Prospects and 1 to Keep Off Your Radar
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses. Navigating this part of the market can be tricky, which is why we built StockStory to help you separate the winners from the laggards. That said, here are two Russell 2000 stocks that could be the next breakout winners and one that may face some trouble. Market Cap: $1.95 billion Started with a dozen Model T Fords, Hertz (NASDAQ:HTZ) is a global car rental company providing vehicle rental services to leisure and business travelers. Why Do We Pass on HTZ? Weak unit sales over the past two years indicate demand is soft and that the company may need to revise its strategy Eroding returns on capital suggest its historical profit centers are aging Unfavorable liquidity position could lead to additional equity financing that dilutes shareholders Hertz is trading at $6.30 per share, or 5.3x forward EV-to-EBITDA. If you're considering HTZ for your portfolio, see our FREE research report to learn more. Market Cap: $8.39 billion Founded in 1999 and named after a naval term for a flag-bearing ship, The Ensign Group (NASDAQ:ENSG) operates skilled nursing facilities, senior living communities, and rehabilitation services across 15 states, primarily serving high-acuity patients recovering from various medical conditions. Why Could ENSG Be a Winner? Unit sales averaged 13.2% growth over the past two years and imply healthy demand for its products Estimated revenue growth of 14.3% for the next 12 months implies its momentum over the last two years will continue Earnings per share grew by 18.4% annually over the last five years and trumped its peers The Ensign Group's stock price of $147.04 implies a valuation ratio of 22.8x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it's free. Market Cap: $1.33 billion Founded in 2009, Integral Ad Science (NASDAQ:IAS) provides digital advertising verification and optimization solutions, ensuring that ads are viewable by real people in brand-safe environments across various platforms and devices. Why Do We Like IAS? Software platform has product-market fit given the rapid recovery of its customer acquisition costs Operating profits increased over the last year as the company gained some leverage on its fixed costs and became more efficient Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends At $8.35 per share, Integral Ad Science trades at 2.2x forward price-to-sales. Is now the right time to buy? Find out in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Business
- Yahoo
AMN Healthcare Services (AMN) Q1 Earnings: What To Expect
Healthcare staffing company AMN Healthcare Services (NYSE:AMN) will be reporting earnings tomorrow after market hours. Here's what you need to know. AMN Healthcare Services beat analysts' revenue expectations by 5.8% last quarter, reporting revenues of $734.7 million, down 10.2% year on year. It was a strong quarter for the company, with an impressive beat of analysts' EPS estimates. Is AMN Healthcare Services a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting AMN Healthcare Services's revenue to decline 18.4% year on year to $670.1 million, improving from the 27.1% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.21 per share. AMN Healthcare Services Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. AMN Healthcare Services has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 1.5% on average. Looking at AMN Healthcare Services's peers in the healthcare providers & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Pediatrix Medical Group's revenues decreased 7.4% year on year, beating analysts' expectations by 1.6%, and The Ensign Group reported revenues up 16.1%, in line with consensus estimates. The Ensign Group's stock price was unchanged following the results. Read our full analysis of Pediatrix Medical Group's results here and The Ensign Group's results here. There has been positive sentiment among investors in the healthcare providers & services segment, with share prices up 5.9% on average over the last month. AMN Healthcare Services is up 2.3% during the same time and is heading into earnings with an average analyst price target of $28.57 (compared to the current share price of $19.91). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
07-05-2025
- Business
- Yahoo
The Pennant Group (NASDAQ:PNTG) Beats Expectations in Strong Q1
Senior living provider The Pennant Group (NASDAQ:PNTG) announced better-than-expected revenue in Q1 CY2025, with sales up 33.7% year on year to $209.8 million. Its non-GAAP profit of $0.27 per share was 13.7% above analysts' consensus estimates. Is now the time to buy The Pennant Group? Find out in our full research report. The Pennant Group (PNTG) Q1 CY2025 Highlights: Revenue: $209.8 million vs analyst estimates of $201.5 million (33.7% year-on-year growth, 4.1% beat) Adjusted EPS: $0.27 vs analyst estimates of $0.24 (13.7% beat) Adjusted EBITDA: $16.37 million vs analyst estimates of $14.22 million (7.8% margin, 15.2% beat) Operating Margin: 6%, up from 5% in the same quarter last year Sales Volumes rose 28.9% year on year (34.3% in the same quarter last year) Market Capitalization: $928.4 million 'We are off to a strong start in 2025,' said Brent Guerisoli, the Company's Chief Executive Officer. Company Overview Spun off from The Ensign Group in 2019 to focus on non-skilled nursing healthcare services, Pennant Group (NASDAQ:PNTG) operates home health, hospice, and senior living facilities across 13 western and midwestern states, serving patients of all ages including seniors. Sales Growth Reviewing a company's long-term sales performance reveals insights into its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Thankfully, The Pennant Group's 16.2% annualized revenue growth over the last five years was solid. Its growth beat the average healthcare company and shows its offerings resonate with customers. The Pennant Group Quarterly Revenue Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. The Pennant Group's annualized revenue growth of 24.1% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated. The Pennant Group Year-On-Year Revenue Growth We can better understand the company's revenue dynamics by analyzing its number of admissions, which reached 18,878 in the latest quarter. Over the last two years, The Pennant Group's admissions averaged 25.1% year-on-year growth. Because this number is in line with its revenue growth, we can see the company kept its prices fairly consistent. The Pennant Group Admissions This quarter, The Pennant Group reported wonderful year-on-year revenue growth of 33.7%, and its $209.8 million of revenue exceeded Wall Street's estimates by 4.1%. Looking ahead, sell-side analysts expect revenue to grow 13.4% over the next 12 months, a deceleration versus the last two years. Still, this projection is noteworthy and implies the market is forecasting success for its products and services.
Business Insider
03-05-2025
- Business
- Business Insider
RBC Capital Sticks to Its Buy Rating for The Ensign Group (ENSG)
RBC Capital analyst Ben Hendrix maintained a Buy rating on The Ensign Group (ENSG – Research Report) on May 1 and set a price target of $177.00. The company's shares closed yesterday at $132.32. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Hendrix is a 3-star analyst with an average return of 1.7% and a 47.55% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Tenet Healthcare, Brookdale Senior Living, and Chemed. Currently, the analyst consensus on The Ensign Group is a Strong Buy with an average price target of $166.00. ENSG market cap is currently $7.37B and has a P/E ratio of 24.07.
Yahoo
29-04-2025
- Business
- Yahoo
The Ensign Group's (NASDAQ:ENSG) Q1 Earnings Results: Revenue In Line With Expectations
Healthcare services company The Ensign Group (NASDAQ:ENSG). met Wall Street's revenue expectations in Q1 CY2025, with sales up 16.1% year on year to $1.17 billion. Its non-GAAP profit of $1.52 per share was 1.9% above analysts' consensus estimates. Is now the time to buy The Ensign Group? Find out in our full research report. Revenue: $1.17 billion vs analyst estimates of $1.17 billion (16.1% year-on-year growth, in line) Adjusted EPS: $1.52 vs analyst estimates of $1.49 (1.9% beat) Adjusted EBITDA: $137.4 million vs analyst estimates of $133.7 million (11.7% margin, 2.8% beat) Operating Margin: 8.6%, in line with the same quarter last year Sales Volumes rose 12.5% year on year (10.1% in the same quarter last year) Market Capitalization: $7.32 billion 'We are thrilled to announce another record setting quarter achieved by our local teams. In spite of all the industry noise, our results this quarter demonstrate that we've never been stronger, showing yet again that sound fundamentals coupled with incredible passion can forge consistency even in an ever-changing environment. Our operators set several all-time highs during the quarter, which are only made possible by strong clinical outcomes achieved by our dedicated team of our caregivers and front-line staff,' said Barry Port, Ensign's Chief Executive Officer. Founded in 1999 and named after a naval term for a flag-bearing ship, The Ensign Group (NASDAQ:ENSG) operates skilled nursing facilities, senior living communities, and rehabilitation services across 15 states, primarily serving high-acuity patients recovering from various medical conditions. A company's long-term sales performance can indicate its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Thankfully, The Ensign Group's 15.5% annualized revenue growth over the last five years was solid. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. The Ensign Group's annualized revenue growth of 17.6% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated. We can better understand the company's revenue dynamics by analyzing its number of units sold, which reached 2.54 million in the latest quarter. Over the last two years, The Ensign Group's units sold averaged 13.2% year-on-year growth. Because this number is lower than its revenue growth, we can see the company benefited from price increases. This quarter, The Ensign Group's year-on-year revenue growth was 16.1%, and its $1.17 billion of revenue was in line with Wall Street's estimates. Looking ahead, sell-side analysts expect revenue to grow 12.8% over the next 12 months, a deceleration versus the last two years. Still, this projection is admirable and implies the market sees success for its products and services. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes. The Ensign Group was profitable over the last five years but held back by its large cost base. Its average operating margin of 8.7% was weak for a healthcare business. Analyzing the trend in its profitability, The Ensign Group's operating margin might fluctuated slightly but has generally stayed the same over the last five years, meaning it will take a fundamental shift in the business model to change. This quarter, The Ensign Group generated an operating profit margin of 8.6%, in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. The Ensign Group's EPS grew at an astounding 18.4% compounded annual growth rate over the last five years, higher than its 15.5% annualized revenue growth. However, we take this with a grain of salt because its operating margin didn't expand and it didn't repurchase its shares, meaning the delta came from reduced interest expenses or taxes. In Q1, The Ensign Group reported EPS at $1.52, up from $1.30 in the same quarter last year. This print beat analysts' estimates by 1.9%. Over the next 12 months, Wall Street expects The Ensign Group's full-year EPS of $5.72 to grow 12.7%. It was good to see The Ensign Group narrowly top analysts' sales volume expectations this quarter. EPS also beat. Overall, this quarter had some key positives. The stock remained flat at $129.42 immediately following the results. Is The Ensign Group an attractive investment opportunity right now? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
